Participate in a Groundbreaking Non-Invasive Imaging Trial
A diagnosis of HR-/HER2+ breast cancer can be scary, and identifying the right course of action is overwhelming. That’s why research is so important!
BAMF Health is at the forefront of research. We are launching a non-invasive imaging clinical trial for those with HR-/HER2+ metastatic breast cancer. This trial aims to understand the prevalence of a specific biomarker in this subset of breast cancer. We invite you to apply.
Women with breast cancer deserve more options—help us get there faster.
Eligibility and Benefits
Eligibility Criteria
- At least 18 years old
- Diagnosed with HR-/HER2+ metastatic breast cancer
- At least one measurable tumor lesion on conventional imaging
- Women of childbearing potential must have a negative pregnancy test
Benefits to Participating
- Receive an advanced PET scan at BAMF Health
- Images will be sent to your doctor
- $500 stipend provided
- The opportunity to advance options for women diagnosed with breast cancer
Let's Advance Research Together!
BAMF Health Clinical Trial Updates
Lung Cancer Patient is First in the World to Participate in New Therapy Trial
Angela is the first person in the world to participate in a new clinical trial exploring an investigational radiopharmaceutical therapy.
May 20, 2026
Henry Ford Health and BAMF Health Break Ground on Comprehensive Theranostics Center in Downtown Detroit
BAMF Health and Henry Ford Health officially broke ground on a 45,000-square-foot facility.
April 14, 2026
World Traveler Becomes First-in-World Patient
Bill was the first patient in the world to participate in a clinical trial exploring an experimental radiopharmaceutical therapy for prostate cancer.
January 26, 2026